Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Account Payables: 2013-2024

Historic Change in Account Payables for Iovance Biotherapeutics (IOVA) over the last 12 years, with Dec 2024 value amounting to -$7.8 million.

  • Iovance Biotherapeutics' Change in Account Payables fell 130.43% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 177.90%. This contributed to the annual value of -$7.8 million for FY2024, which is 262.41% down from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Change in Account Payables is -$7.8 million, which was down 262.41% from $4.8 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Change in Account Payables high stood at $7.0 million for FY2021, and its period low was -$7.8 million during FY2024.
  • Over the past 3 years, Iovance Biotherapeutics' median Change in Account Payables value was $4.8 million (recorded in 2023), while the average stood at $956,667.
  • In the last 5 years, Iovance Biotherapeutics' Change in Account Payables spiked by 335.36% in 2021 and then crashed by 262.41% in 2024.
  • Over the past 5 years, Iovance Biotherapeutics' Change in Account Payables (Yearly) stood at -$3.0 million in 2020, then soared by 335.36% to $7.0 million in 2021, then decreased by 15.67% to $5.9 million in 2022, then fell by 17.93% to $4.8 million in 2023, then tumbled by 262.41% to -$7.8 million in 2024.